Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.

ABSTRACT:

Background and aims

We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in patients with Crohn's disease [CD] in stable clinical and biochemical remission.

Design

We conducted a pragmatic, open-label, randomized controlled non-inferiority trial, comparing increased adalimumab intervals with the 2-weekly interval in adult CD patients in clinical remission. Quality of life was measured with the EQ-5D-5L. Costs were measured from a societal perspective. Results are shown as differences and incremental net monetary benefit [iNMB] at relevant willingness to accept [WTA] levels.

Results

We randomized 174 patients to the intervention [n = 113] and control [n = 61] groups. No difference was found in utilit

SUBMITTER: Jansen FM 

PROVIDER: S-EPMC10673815 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature